Is Achieve Life Sciences, Inc. overvalued or undervalued?

As of 31 July 2017, the valuation grade for Achieve Life Sciences, Inc. moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently considered overvalued, given its negative financial metrics, including a P/E ratio that is not applicable due to losses, a Price to Book Value of 12.92, and an EV to EBITDA of -2.61.
In comparison to its peers, Achieve Life Sciences shows a less favorable position; for instance, Abeona Therapeutics, Inc. has an EV to EBITDA of -3.6927, while MediWound Ltd. has a more severe EV to EBITDA of -9.0843. The company's return metrics also reflect its struggles, with a 1-year stock return of -22.74% compared to a 10.26% return for the S&P 500, highlighting its underperformance in the market. Overall, the combination of poor ratios and negative returns suggests that Achieve Life Sciences, Inc. is overvalued in its current state.